Drug intelligence / Profile preview

TOP-1

Development stage: Preclinical
Lead developer: Imagine Pharma
Modality: Peptides
Administration: Topical

Overview

TOP-1 is a topical therapeutic developed by Imagine Pharma that utilizes the company's proprietary IMG-1 polypeptide platform. It is specifically designed to accelerate re-epithelialization and healing of partial thickness skin donor sites in patients undergoing skin graft procedures. By facilitating faster wound closure, the therapy aims to reduce patient pain and decrease the time required for donor site recovery. The IMG-1 polypeptide serves as both the active ingredient and the biological target in this application. As a polypeptide-based treatment, TOP-1 is classified as a biologic modality and is currently part of Imagine Pharma's regenerative medicine and therapeutics pipeline.

Other names: skin graft TOP-1TOP-1 Skin GraftTOP1 Skin GraftTOP 1 Skin Graft

Beyond the preview

Go deeper on TOP-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TOP-1.

Explore the full profile